Foundational contributions of Svetlana Mojsov to the GLP-1 field

Biochemist Svetlana Mojsov, both as a graduate student at The Rockefeller University under the mentorship of Bruce Merrifield during the 1970s, and as an independent investigator at the Massachusetts General Hospital (MGH) during the 1980s, devised effective and robust methods for the chemical synth...

Full description

Saved in:
Bibliographic Details
Main Authors: George Barany, Michael J. Barany
Format: Article
Language:English
Published: Open Exploration 2024-10-01
Series:Exploration of Drug Science
Subjects:
Online Access:https://www.explorationpub.com/uploads/Article/A100869/100869.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1825199611880407040
author George Barany
Michael J. Barany
author_facet George Barany
Michael J. Barany
author_sort George Barany
collection DOAJ
description Biochemist Svetlana Mojsov, both as a graduate student at The Rockefeller University under the mentorship of Bruce Merrifield during the 1970s, and as an independent investigator at the Massachusetts General Hospital (MGH) during the 1980s, devised effective and robust methods for the chemical synthesis of the peptide hormones glucagon and glucagon-like peptide (GLP-1), along with numerous analogues of these key biomolecules. Working separately from MGH’s powerhouse endocrine research laboratory, Mojsov developed a tool-kit of reliable assays that were indispensable to later in vitro and in vivo collaborative studies that established profound insulinotropic effects of this peptide family, findings that were subsequently harnessed clinically with blockbuster drugs directed at often-serious endocrine conditions such as type 2 diabetes and obesity. Significantly, Mojsov was the first to recognize the critical cleavage sites in preproglucagon that give rise to the biologically active species, a truncated form known as GLP-1 (7–37), and carried out the key experiments that proved her hypothesis. Despite being the first author on critical formative publications for the field, and being acknowledged, along with Joel Habener, as one of two co-inventors on the controlling United States patents, Mojsov’s foundational contributions were initially overlooked when GLP-1 biochemistry began to be the subject of major scientific prizes. Fortunately, Mojsov’s work has, within the past year, been better appreciated and deservedly lauded.
format Article
id doaj-art-cd378c6d12984e63a4de07d0767b1e8c
institution Kabale University
issn 2836-7677
language English
publishDate 2024-10-01
publisher Open Exploration
record_format Article
series Exploration of Drug Science
spelling doaj-art-cd378c6d12984e63a4de07d0767b1e8c2025-02-08T03:29:24ZengOpen ExplorationExploration of Drug Science2836-76772024-10-012668870010.37349/eds.2024.00069Foundational contributions of Svetlana Mojsov to the GLP-1 fieldGeorge Barany0https://orcid.org/0000-0002-6373-2706Michael J. Barany1https://orcid.org/0000-0002-4067-5112Department of Chemistry, University of Minnesota, Minneapolis, MN 55455, USAScience, Technology and Innovation Studies Subject Group, University of Edinburgh, EH8 9LD Edinburgh, United KingdomBiochemist Svetlana Mojsov, both as a graduate student at The Rockefeller University under the mentorship of Bruce Merrifield during the 1970s, and as an independent investigator at the Massachusetts General Hospital (MGH) during the 1980s, devised effective and robust methods for the chemical synthesis of the peptide hormones glucagon and glucagon-like peptide (GLP-1), along with numerous analogues of these key biomolecules. Working separately from MGH’s powerhouse endocrine research laboratory, Mojsov developed a tool-kit of reliable assays that were indispensable to later in vitro and in vivo collaborative studies that established profound insulinotropic effects of this peptide family, findings that were subsequently harnessed clinically with blockbuster drugs directed at often-serious endocrine conditions such as type 2 diabetes and obesity. Significantly, Mojsov was the first to recognize the critical cleavage sites in preproglucagon that give rise to the biologically active species, a truncated form known as GLP-1 (7–37), and carried out the key experiments that proved her hypothesis. Despite being the first author on critical formative publications for the field, and being acknowledged, along with Joel Habener, as one of two co-inventors on the controlling United States patents, Mojsov’s foundational contributions were initially overlooked when GLP-1 biochemistry began to be the subject of major scientific prizes. Fortunately, Mojsov’s work has, within the past year, been better appreciated and deservedly lauded.https://www.explorationpub.com/uploads/Article/A100869/100869.pdfglucagon-like peptide 1 (glp-1)glucagontype 2 diabetesobesitysolid-phase peptide synthesis (spps)scientific discoverycredit and recognition
spellingShingle George Barany
Michael J. Barany
Foundational contributions of Svetlana Mojsov to the GLP-1 field
Exploration of Drug Science
glucagon-like peptide 1 (glp-1)
glucagon
type 2 diabetes
obesity
solid-phase peptide synthesis (spps)
scientific discovery
credit and recognition
title Foundational contributions of Svetlana Mojsov to the GLP-1 field
title_full Foundational contributions of Svetlana Mojsov to the GLP-1 field
title_fullStr Foundational contributions of Svetlana Mojsov to the GLP-1 field
title_full_unstemmed Foundational contributions of Svetlana Mojsov to the GLP-1 field
title_short Foundational contributions of Svetlana Mojsov to the GLP-1 field
title_sort foundational contributions of svetlana mojsov to the glp 1 field
topic glucagon-like peptide 1 (glp-1)
glucagon
type 2 diabetes
obesity
solid-phase peptide synthesis (spps)
scientific discovery
credit and recognition
url https://www.explorationpub.com/uploads/Article/A100869/100869.pdf
work_keys_str_mv AT georgebarany foundationalcontributionsofsvetlanamojsovtotheglp1field
AT michaeljbarany foundationalcontributionsofsvetlanamojsovtotheglp1field